» Articles » PMID: 10372118

Effects of CC, CXC, C, and CX3C Chemokines on Proliferation of Myeloid Progenitor Cells, and Insights into SDF-1-induced Chemotaxis of Progenitors

Overview
Specialty Science
Date 1999 Jun 18
PMID 10372118
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokines have been implicated in the regulation of stem/progenitor cell proliferation and movement. The purpose of the present study was to assess a number of new chemokines for suppressive activity and to delve further into SDF-1-mediated chemotaxis of progenitor cells. This report extends the list of chemokines that have suppressive activity against immature subsets of myeloid progenitors stimulated to proliferate by multiple growth factors to include: MCP-4/CK beta-10, MIP-4/CK beta-7, I-309, TECK, GCP-2, MIG and lymphotactin. The suppressive activity of a number of other chemokines was confirmed. Additionally, pretreatment of the active chemokines with an acetylnitrile solution enhanced specific activity of a number of these chemokines. The new chemokines found to be lacking suppressive activity include: MCP-2, MCP-3, eotaxin-1, MCIF/HCC-1/CK beta-1, TARC, MDC, MPIF-2/eotaxin-2/CK beta-6, SDF-1 and fractalkine/neurotactin. Overall, 19 chemokines, crossing the CC, CXC, and C subgroups, have now been found to be myelosuppressive, and 14 chemokines crossing the CC, CXC and CX3C subgroups have been found to lack myelosuppressive activity under the culture conditions of our assays. Because of the redundancy in chemokine/chemokine receptor interactions, it is not yet clear through which chemokine receptors many of these chemokines signal to elicit suppressive activities. It was also found that SDF-1-induced chemotaxis of progenitors can occur in the presence of fibronectin (FN) and extracellular matrix components and that FN effects involve activation of beta 1-, and possibly alpha 4-, integrins.

Citing Articles

CXCL15/Lungkine has suppressive activity on proliferation and expansion of multi-potential, erythroid, granulocyte and macrophage progenitors in S-phase specific manner.

Broxmeyer H, Cooper S, Ropa J Blood Cells Mol Dis. 2021; 91:102594.

PMID: 34520986 PMC: 9231597. DOI: 10.1016/j.bcmd.2021.102594.


A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease.

Capitano M, Jaiswal A, Broxmeyer H, Pride Y, Glover S, Amlashi F PLoS One. 2021; 16(7):e0252805.

PMID: 34197491 PMC: 8248966. DOI: 10.1371/journal.pone.0252805.


HbF Levels in Sickle Cell Disease Are Associated with Proportion of Circulating Hematopoietic Stem and Progenitor Cells and CC-Chemokines.

Minniti C, Tolu S, Wang K, Yan Z, Robert K, Zhang S Cells. 2020; 9(10).

PMID: 33003401 PMC: 7650715. DOI: 10.3390/cells9102199.


Platelets Boost Recruitment of CD133 Bone Marrow Stem Cells to Endothelium and the Rodent Liver-The Role of P-Selectin/PSGL-1 Interactions.

Lehwald N, Duhme C, Pinchuk I, Kirchner J, Wieferich K, Schmelzle M Int J Mol Sci. 2020; 21(17).

PMID: 32899390 PMC: 7504029. DOI: 10.3390/ijms21176431.


Discovery of CCL18 antagonist blocking breast cancer metastasis.

Liu Y, Zheng H, Li Q, Li S, Lai H, Song E Clin Exp Metastasis. 2019; 36(3):243-255.

PMID: 31062206 DOI: 10.1007/s10585-019-09965-2.